Cargando…

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience

SIMPLE SUMMARY: The continuum of care for mCRC might include anti-angiogenic drug as anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine-based regimens in first- and second-line treatment, and multikinase inhibitors in refractory patients. The addition of aflibercept t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lavacchi, Daniele, Roviello, Giandomenico, Giommoni, Elisa, Dreoni, Lorenzo, Derio, Silvia, Brugia, Marco, Amedei, Amedeo, Pillozzi, Serena, Antonuzzo, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345481/ https://www.ncbi.nlm.nih.gov/pubmed/34359764 http://dx.doi.org/10.3390/cancers13153863

Ejemplares similares

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
por: Paderi, Agnese, et al.
Publicado: (2021)

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
por: Lavacchi, Daniele, et al.
Publicado: (2023)

A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
por: Hasic Telalovic, Jasminka, et al.
Publicado: (2021)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
por: Giommoni, Elisa, et al.
Publicado: (2021)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
por: Joulain, F, et al.
Publicado: (2013)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
por: Salvianti, Francesca, et al.
Publicado: (2021)

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
por: Fancelli, Sara, et al.
Publicado: (2021)

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
por: Hamaguchi, Tetsuya, et al.
Publicado: (2019)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Catalano, Martina, et al.
Publicado: (2020)

Results of the observational prospective RealFLOT study
por: Giommoni, Elisa, et al.
Publicado: (2021)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

Systemic Sclerosis Association with Malignancy
por: Lepri, Gemma, et al.
Publicado: (2022)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Paderi, Agnese, et al.
Publicado: (2021)

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
por: Denda, Tadamichi, et al.
Publicado: (2019)

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018)

Electronic nicotine delivery systems (ENDS): not still ready to put on END
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
por: Satake, Hironaga, et al.
Publicado: (2020)

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
por: Rubino, Rossella, et al.
Publicado: (2021)

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
por: Devaux, Madeline, et al.
Publicado: (2019)

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies
por: Nakatsumi, Hiroshi, et al.
Publicado: (2022)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
por: Fernández Montes, Ana, et al.
Publicado: (2019)

Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure
por: Aggarwal, Shyam
Publicado: (2015)

Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report
por: Gonzaga-López, A, et al.
Publicado: (2017)

Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
por: Watanabe, Jun, et al.
Publicado: (2022)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
por: Hofheinz, Ralf-Dieter, et al.
Publicado: (2022)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
por: Lavacchi, Daniele, et al.
Publicado: (2023)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_06b1lnsaiik06bq3snhhqgvjd6